The incorporation of alternative HCC treatment options such as stereotactic body radiation therapy (SBRT) or systemic treatments without antiangiogenic drugs such as anti-PD1/PDL1 [45,46,47,48,49] that were not available during the study period may currently benefit elderly patients with preserved liver function and preserved performance status. This evidence concerns the gene CD274 and hepatocellular carcinoma.